Successful results for Tecentriq + Avastin versus sunitinib in IMmotion151 study for renal cell cancer.- Genentech/Roche.

Genentech, a member of the Roche Group announced results from the positive Phase III IMmotion151 study of Tenctriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). The study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: expression (greater than ? 1 percent) protein. Those who received Tecentriq plus Avastin had a 26-percent reduced risk of disease worsening or death (PFS) compared to people treated with sunitinib (median PFS [mPFS]: 11.2 vs. 7.7 months; HR=0.74; 95 percent CI 0.57, 0.96; p=0.02). Initial observations from the co-primary endpoint of overall survival (OS) in the overall study population (intention-to-treat, ITT) were encouraging, but are still immature.

Safety for the Tecentriq and Avastin combination appeared consistent with the known safety profile of the individual medicines and what was previously reported in the Phase II IMmotion150 study. No new safety signals were identified with the combination. The rate of treatment-related Grade 3-4 adverse events was lower with the Tecentriq and Avastin combination (40 percent) than with sunitinib alone (54 percent) in all treated patients.